Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium
March 24th, 2023
This article describes a protocol to simplify the process and render the preparation of autologous conditioned serum (ACS) less expensive. No special syringes or surface-coated glass beads are needed. Moreover, the modified ACS (mACS) has competitive advantages over conventional autologous serum in the corneal wound healing of murine eyes ex vivo.
This process presents an innovative blood derived product called mACS, which does not require any complex technical processing. It also accelerates wound healing to a greater extent than conventional autologous serum. In addition to providing a standardized preparation process, this technique can also reduce the cost of serum eyedrops, improving patient accessibility to a more affordable treatment option.
This technique may be applied in fields that require promoting wound or tissue regeneration, repair, and anti-inflammation. This technique will be a great advantage for difficult to heal wounds and chronic inflammatory diseases such as severe ocular surface diseases. To begin, inject 10 milliliters of the previously drawn human venous blood into each of the six vacutainer tubes.
Place the tubes in an incubator at 37 degrees Celsius for four hours and then centrifuge the tubes at 3, 500 G for 10 minutes at room temperature. Decap the tubes after placing them on the rack. After putting on sterile gloves, use a three milliliter syringe equipped with an 18 gauge needle to draw out the mACS from each tube.
Pull out the needle and attach a 0.22 micrometer filter. Connect the 23 gauge, 1.5 inch blood collection needle with the original three milliliter syringe to the outlet of the filter. Push the needle gently through the filter into the prepared sterile eyedrop bottles for immediate use, store the eyedrops at four degrees Celsius.
In the ex-vivo surface healing model, subjects treated with the mACS eyedrops displayed superior corneal healing relative to those treated with the autologous serum drops. At 16 hours, the corneal wounds of all groups healed slower than the one treated with 0.5%mACS. The murine cornea of the DMEM groups and autologous serum at 24 hours demonstrated comparable healing with mACSS at 32 hours except for the normal saline group.
All other groups showed close to full recovery. The most important step is to follow aseptic procedures during the process. Serum products are rich in nutrients so using contaminated products on the cornea can cause severe corneal ulcers.
This product can be used to assess the healing of wounds and the improvement of ocular surface disease symptoms. Analyzing the cytokine component and conducting larger randomized controlled trials of mACS are essential for further research.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a protocol for preparing modified autologous conditioned serum (mACS) that simplifies the process and reduces costs. The mACS demonstrates superior wound healing capabilities compared to conventional autologous serum in murine corneal models.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Wound healing
Background
- Autologous conditioned serum (ACS) is used for ocular surface diseases.
- Conventional preparation methods can be complex and costly.
- mACS offers a simplified and cost-effective alternative.
- Improved accessibility for patients needing serum eyedrops.
Purpose of Study
- To develop a standardized preparation process for mACS.
- To evaluate the effectiveness of mACS in promoting wound healing.
- To enhance patient access to affordable treatment options.
Methods Used
- Collection of human venous blood.
- Preparation of mACS without special syringes or coatings.
- Application of mACS in ex vivo murine corneal wound healing models.
- Comparison of mACS with conventional autologous serum.
Main Results
- mACS accelerates wound healing more effectively than conventional serum.
- Standardized preparation reduces costs associated with serum eyedrops.
- mACS can be beneficial for chronic inflammatory diseases.
- Potential applications in various fields requiring tissue regeneration.
Conclusions
- mACS is a viable alternative to conventional autologous serum.
- The protocol enhances accessibility and affordability for patients.
- Further research may expand its applications in wound healing.
Frequently Asked Questions
Executive Industry Relevance
Standardized preparation of modified autologous conditioned serum (mACS) offers a reproducible, cost-effective solution for evaluating wound healing in preclinical ocular models. This approach addresses the need for scalable, accessible blood-derived therapeutics in early-stage discovery and translational research. The protocol supports portfolio decisions by enabling comparative assessment of regenerative and anti-inflammatory potential in disease-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses for wound healing and tissue regeneration.
- Supports biological de-risking by providing a standardized, reproducible serum preparation.
- Facilitates functional validation of immune-modulating properties in ex vivo models.
Screening & Assay Development
- Prepares validated biological reagents for quantitative assessment of corneal healing.
- Improves assay reproducibility and standardization across experimental runs.
- Enables reliable comparison of mACS versus conventional serum in controlled settings.
Translational & Preclinical Research
- Aligns with disease-relevant models for ocular surface and chronic inflammatory conditions.
- Supports continuity from ex vivo efficacy to in vivo and clinical evaluation pipelines.
- Provides a platform for biomarker and cytokine analysis in regenerative research.
Pipeline & Workflow Integration
The mACS protocol integrates into the discovery-to-preclinical continuum, supporting early validation and downstream translational studies.
- Discovery Biology: Facilitates hypothesis testing for regenerative and anti-inflammatory mechanisms.
- Screening: Delivers standardized, quantitative healing readouts for comparative analysis.
- Analytics: Enables measurement of wound closure rates and cytokine profiles.
- Translational Research: Bridges ex vivo findings to in vivo and clinical trial readiness.
- Enterprise Reuse: Establishes a reproducible serum preparation platform for diverse tissue repair studies.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in wound healing and anti-inflammatory efficacy.
- Operational Value: Reduces cost and complexity of serum preparation, improving scalability.
- Strategic Value: Supports robust go/no-go decisions for regenerative therapy candidates.
- Portfolio Impact: Enables risk-adjusted prioritization of blood-derived therapeutics for ocular and inflammatory indications.
Implementation Considerations
- Requires expertise in aseptic blood handling and serum processing.
- Needs access to standard laboratory centrifugation and filtration equipment.
- Demands strict adherence to sterility to prevent contamination risks.
- Adaptable to various preclinical models with protocol standardization.
- Dependent on further cytokine analysis and larger-scale validation for broader adoption.
